Alimera Sciences (NASDAQ:ALIM – Get Rating) was downgraded by Alliance Global Partners from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Monday, The Fly reports. They presently have a $4.50 price target on the biopharmaceutical company’s stock, down from their previous price target of $11.00. Alliance […]
